Renin inhibitors in diabetes and hypertension: an update by Şen, Selçuk et al.
EXCLI Journal 2014;13:1111-1119 – ISSN 1611-2156 
Received: July 22, 2014, accepted: August 19, 2014, published: September 24, 2014 
 
 
1111 
Review article: 
RENIN INHIBITORS IN DIABETES AND HYPERTENSION:  
AN UPDATE 
 
Selçuk Şen, Baran Ufuktepe, Zeynep Güneş Özünal, Yağız Üresin* 
 
Department of Medical Pharmacology, Istanbul Faculty of Medicine, Istanbul University,  
Istanbul, Turkey 
 
* Corresponding author: Yağız Üresin, Department of Medical Pharmacology,  
Istanbul Faculty of Medicine, Turgut Ozal Street 34390, Capa, Istanbul, Turkey,  
e-mail: yagiz@istanbul.edu.tr 
 
 
ABSTRACT 
The coexistence of hypertension and diabetes increases the incidence of cardiovascular events 
and long-term morbidity and mortality. Blood pressure should be controlled with the most 
appropriate drugs as well as tight blood glucose control in patients with diabetes and hyper-
tension. RAAS (Renin Angiotensin Aldosterone System) blockers have an important role in 
the treatment of these patients, in this sense, ACEi and ARB remained the major treatment 
option in hypertension guidelines. The most recent RAAS blocker to be approved by the FDA 
was aliskiren in 2007, a renin inhibitor. Studies showed that aliskiren is as effective as other 
antihypertensive drugs and has a safety profile similar to placebo. The potent renin inhibitor 
aliskiren directly inhibits the RAAS system at its rate limiting step and differently from other 
RAAS blockers; it decreases plasma renin activity (PRA). Although the relationship of in-
creased PRA levels and cardiovascular risk has been shown, it is unclear if the PRA decrease 
provided by aliskiren has an impact on clinical outcomes and cardiovascular endpoints. On 
the other hand, large trials like ASPIRE, AVANT-GARDE, ALTITUDE, ASTRONAUT, 
which investigated the combination of aliskiren with other RAAS blockers, failed to show the 
expected outcomes or resulted with an increased incidence of adverse effects, which raised 
more questions. As a result of the ALTITUDE trial, combination of aliskiren with an ACEi or 
ARB is not recommended in patients with hypertension and diabetes, or at least moderate re-
nal dysfunction. Trials designed to prove aliskiren’s efficacy in new indications like diabetes, 
may face similar problems related to dual RAAS blockade because in the majority of cases, 
the optimal treatment is achieved with an ACEi or ARB. In this conjuncture, the increase in 
adverse events seen with aliskiren might be related to dual RAAS blockade rather than 
aliskiren directly. For instance, it is unclear whether the adverse event incidence would be the 
same, less, or higher if ALTITUDE was designed to investigate ACEi and ARB combination 
without aliskiren. In fact, every new molecular entity and mechanism of action faces the same 
barriers. For the time being, differentiating points like PRA lowering effects as an add-on 
therapy to calcium channel blockers or hydrochlorothiazide, and the populations that might 
have additional benefit, should be carefully investigated. 
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INTRODUCTION 
Hypertension is the most frequent condi-
tion in primary care settings that results with 
myocardial infarction, renal failure, stroke, 
retinopathy, and death if underdiagnosed or 
treated inappropriately. Diabetes Mellitus is 
as chronic, complex, and common disease as 
hypertension.  Incidence of both in the same 
patient makes the outcomes worse. 
The etiology of diabetes complications 
was unclear and much discussed until the 
1990s. During that period, clinical trials 
demonstrated that intensive control of blood 
glucose in diabetes was correlated with mi-
crovascular complication decrease and angi-
otensin converting enzyme inhibitor (ACEi), 
independent from blood pressure (BP) low-
ering effects, reduced the progression of dia-
betic complications (Hsueh and Wyne, 
2011). Nowadays, it is widely known that 
RAAS (Renin Angiotensin Aldosterone Sys-
tem) blocking agents prevent or delay the 
onset of diabetes complications. Moreover, 
trials with RAAS blockade and guidelines 
allowed ACEi and angiotensin II receptor 
blockers (ARB) to be the first-line treatment 
options in patients with hypertension and 
diabetes. 
Diabetes and hypertension both affect the 
vascular tree and deteriorate same target or-
gans including the heart, kidneys, eyes, and 
brain (Grossman and Messerli, 2008).  The 
cardiovascular disease risk is four times 
higher when both diseases are present com-
pared with hypertension alone (Aksnes et al., 
2012). Moreover, Framingham cohort results 
showed that coexistent hypertension is at-
tributed to excess risk of cardiovascular 
events in patients with diabetes (Chen et al. 
2011). Thus, blood pressure targets in diabe-
tes are important for treatment efficacy. The 
most common cause of end stage renal dis-
ease (ESRD) is hypertension and diabetes 
mellitus (Grossman and Messerli, 2008). 
Hypertension and diabetic retinopathy are 
important causes of blindness (Grossman 
and Messerli, 2008). The presence of hyper-
tension and diabetes has a great effect on si-
lent cerebral infarcts (Eguchi et al., 2003). 
As a result of several studies, it is known 
that decreasing blood pressure reduces cardi-
ovascular events. The therapeutic goals for 
diabetic hypertensive patients differ between 
guidelines. According to the recent Ameri-
can Diabetes Association (ADA) guidelines, 
the diabetic patients’ treatment target for 
blood pressure is 140/90, excluding young 
patients (American Diabetes Association, 
2014). In the Eighth Joint National Commit-
tee (JNC 8) guideline “Evidence-Based 
Guideline for the Management of High 
Blood Pressure in Adults,” goals below 
140/90 mm/Hg are recommended for diabet-
ic hypertensive adult patients (James et al., 
2014). Lower diastolic goals are proposed in 
the European Society of Hypertension/The 
European Society of Cardiology (ESH/ESC) 
2013 guidelines for patients diagnosed as 
having diabetes and hypertension at <140/85 
mm/Hg (Mancia et al., 2013). An earlier 
ADA 2013 recommendation was below 
140/80 mm/Hg and the ESH/ESC 2009 re-
commendation was 130/80 mm/Hg.  
Drug therapy recommendations for pa-
tients with diabetes and hypertension in 
ESC/ESH and ADA 2013 guidelines were 
ACEi/ARB; whereas the JNC 8 2014 guide-
lines claim that there is moderate evidence to 
support initiating drug treatments ACEi/ 
ARB/calcium channel blockers (CCB) or 
thiazide-type diuretics (James et al., 2014). 
The ADA 2014 diabetes care recommenda-
tion for pharmacologic therapy for patients 
with diabetes and hypertension includes 
ACEi or ARB, and notes that multiple-drug 
therapy is generally needed to achieve the 
blood pressure goals. Interestingly with evi-
dence level A, ADA 2014 recommends tak-
ing medication at bedtime (American Diabe-
tes Association, 2014). 
The most recently approved RAAS 
blocking antihypertensive is a renin inhibi-
tor, aliskiren. In this review, we discuss the 
use of aliskiren in patients with hypertension 
and diabetes as a monotherapy or in combi-
nation with other agents, the adverse effects 
of aliskiren, dual RAAS blockade, and AL-
TITUDE and some other clinical trials. 
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POTENTIAL ADVANTAGES OF 
ALISKIREN  
It is known that higher plasma renin ac-
tivity is associated with cardiovascular risk. 
Aliskiren, like ACEi and ARB, affects the 
negative feedback of RAAS and increases 
plasma renin concentration (Azizi et al., 
2006). Unlike other antihypertensives ex-
cluding beta blockers, aliskiren decreases 
plasma renin activity (PRA) (Gradman and 
Traub, 2007). Therefore, aliskiren may pro-
vide additional benefit with its unique PRA 
lowering capacity. However, before drawing 
any conclusions, the clinical impact on car-
diovascular end points via the PRA lowering 
effect of aliskiren in clinical trials should be 
documented. On the other hand, the treat-
ment efficacy of aliskiren might be reduced 
due to lower baseline PRA, reactive PRA 
increase or inadequate reduction (Stanton et 
al., 2009). 
Aliskiren has a good safety profile within 
its therapeutic dose range (150 - 300 mg) and 
can be used in patients with renal impair-
ment because of its hepatic elimination. 
Drug interactions are rarely seen. Aliskiren 
should not be used during pregnancy and re-
nal artery stenosis, which is the same for 
ACEi and ARBs. 
In addition, the long half-life of aliskiren 
(nearly 40 h) could put this medicine one 
step ahead of other drugs. In a randomized 
double-blind trial, Palatini and colleagues 
measured 24 h mean ambulatory BP changes 
after a missed dose in 654 patients with hy-
pertension who received aliskiren, ramipril 
or irbesartan. Aliskiren 300 mg maintained 
antihypertensive efficacy over 24 hours. The 
decrease in systolic blood pressure (SBP) 
and diastolic blood pressure (DBP) was bet-
ter maintained with aliskiren 300 mg 
(91/91 %) than irbesartan 300 mg (73/77 %) 
and ramipril 10 mg (64/65 %) (Palatini et al., 
2010). This difference among groups might 
be explained by the long-duration half-life of 
aliskiren.  
 
PRORENIN AND DIABETES 
The function of prorenin, which is a pre-
cursor of renin, was investigated in several 
preclinical studies. Prorenin can be activated 
with or without proteolysis. Proteolytic acti-
vation requires prosegmentin separation. The 
non-proteolytic activation is achieved via 
binding with the recently discovered 
(pro)renin receptor ((P)PR). 
Prorenin levels have been shown to be 
higher in patients with diabetes mellitus with 
microvascular complications. It is shown that 
this increase occurs earlier than high micro-
albumin levels and  prorenin levels can be 
predictive for microalbuminuria, together 
with glycosylated hemoglobin (Danser et al., 
1989; Luetscher et al., 1985). However, the 
reason for the increase in prorenin levels in 
this condition remains unknown. 
On the other hand, studies show that in-
creased prorenin levels are related with the 
development of several pathologic condi-
tions such as heart failure, diabetic nephropa-
thy, and diabetic retinopathy and that proren-
in receptors may have a role in hypertension 
and end organ damage (Saris et al. 2006; 
Véniant et al., 1996). 
All drugs that inhibit (directly or indi-
rectly) the effects of angiotensin II increase 
prorenin levels through inhibition of the neg-
ative feedback loop. However, no data exists 
that shows that this prorenin increase causes 
excessive prorenin binding and harmful ef-
fects. Renin inhibitors bind to the active part 
of the enzyme and inhibits functionally, 
which is different from other antihyperten-
sives (Uresin and Baran, 2009). Aliskiren 
has been shown to be a potent inhibitor of 
mature renin’s free forms and renin or pro-
renin’s receptor bound forms (Biswas et al., 
2010). 
 
TREATMENT EFFICACY AND  
SAFETY OF ALISKIREN 
In the majority of patients, combination 
therapy with at least 2 antihypertensive drugs 
is needed to obtain a BP level below recom-
mended guideline limits. In patients with 
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high initial BP, combination therapy should 
be considered as a prioritized option (Mancia 
et al., 2013). In order to increase the efficacy 
of aliskiren in hypertension, it could be com-
bined with agents that increase PRA such as 
ACEi, diuretics or ARBs (Andersen et al., 
2008; Gradman et al., 2005; Oparil et al., 
2007; Uresin et al., 2007; Villamil et al., 
2007). 
Aliskiren has been shown to have superi-
or or similar efficacy and safety as a mono-
therapy in hypertension versus ACEi, ARB, 
HCTZ and CCB in many studies.  
In a randomized 8 week trial by Villamil 
and colleagues, 2776 patients with hyperten-
sion were treated in 4 treatment arms with 
aliskiren, hydrochlorothiazide (HCTZ), their 
combination, or placebo. Both diastolic and 
systolic BP reduction was significantly better 
(p<.0001 and p<.05 respectively) in the 
combination arm excluding low dose 75 mg 
aliskiren – 12.5 mg HCTZ combination. 
PRA was decreased by aliskiren by up to 
65 %. Conversely, PRA was increased by 
HCTZ by up to 72 %. The combination of 
aliskiren and HCTZ produced a 46.1-63.5 % 
decline in PRA (Villamil et al., 2007). In an-
other study with HCTZ, either 25 or 12.5 mg 
in combination with 300 mg aliskiren 
showed better SBP/DBP decrease (15.9/11.0 
mm/Hg or 13.5/10.5 mm/Hg) than aliskiren 
alone (8.0/7.4 mm/Hg; both p < 0.001). Also, 
tolerability of the combination treatment was 
similar to that of the aliskiren monotherapy 
(Nickenig et al., 2008). Patients with uncon-
trolled hypertension under 25 mg HCTZ 
treatment  had a significant BP decrease after 
administration of 150/25 mg and 300/25 mg 
aliskiren/HCTZ combination (26 % vs 49 
and 58 %, p < .001 both) in an 8-week trial 
with 722 patients (Blumenstein et al., 2009). 
ACCELERATE (Aliskiren and the CCB 
Amlodipine Combination as an Initial 
Treatment Strategy for Hypertension Con-
trol) trial randomized patients in 3 treatment 
arms; aliskiren 150 mg plus placebo, am-
lodipine 5 mg plus placebo and aliskiren 
150 mg plus amlodipine 5 mg. Between 16 
and 32 weeks of the study, all patients were 
treated with 300 mg aliskiren plus 10 mg 
amlodipine. At the 24th week, patients with 
uncontrolled BP were allowed to receive 
HCTZ or placebo. The initial combination 
therapy arm had a 6.5 mm/Hg better SBP 
reduction versus monotherapy groups (p 
< .0001). The Amlodipine monotherapy arm 
had 11.4 % peripheral edema, which was the 
most common reason for withdrawal. Hypo-
tension rates were 0.3 %, 0.6 % and 0.8 % 
with aliskiren, amlodipine, and combination 
arms, respectively (Brown et al., 2011). 
Aliskiren has been compared with ACEi 
in many head-to-head trials. Uresin and col-
leagues compared the efficacy and safety of 
aliskiren in 837 patients with diabetes with 
hypertension. This trial showed that a com-
bination of aliskiren and ramipril was supe-
rior versus aliskiren (p=.043) and ramipril 
alone (p=.004) in decreasing DBP. Also, the 
combination regimen was superior in SBP 
decrease vs ramipril monotherapy (p<.0001), 
but not aliskiren monotherapy (p=.088). 
Considering SBP, aliskiren monotherapy 
was superior to ramipril monotherapy 
(p=.021). Safety and tolerability measures 
were similar among the groups. The most 
common adverse effects seen with aliskiren 
monotherapy were headache (3.2 %), cough 
(2.1 %), nasopharyngitis (3.2 %) and diar-
rhea (1.1 %). Although cough was seen in 
4.7 % of ramipril monotherapy, in the com-
bination arm it was 1.8 %. Hyperkalemia 
was 5.5 %, 2.6 % and 2.2 % in the combina-
tion, ramipril and aliskiren arms, respective-
ly (Uresin et al., 2007).  
In a randomized clinical trial, the anti-
hypertensive effect of aliskiren and valsartan 
alone or in combination was investigated in 
1797 patients. The highest dose combination 
(300 mg of aliskiren and 320 mg of valsar-
tan) reduced the mean DBP significantly bet-
ter than either monotherapy (12.2 mm/Hg 
decrease with combination; versus 9.0 mm/ 
Hg with aliskiren; 9.7 mm/Hg with valsartan 
320 mg; 4.1 mm/Hg decrease with placebo). 
There was no difference in the rates of the 
adverse reactions, including hyperkalemia 
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and increased serum creatinine levels (Oparil 
et al., 2007). 
White and colleagues showed the favora-
ble safety profile of aliskiren in their meta-
analysis. Twelve thousand patients with hy-
pertension from 12 randomized controlled 
trials were pooled to analyze the adverse ef-
fect profile of aliskiren versus ACEi and 
ARB. Long-term adverse events were lower 
with aliskiren 150 mg and aliskiren 300 mg 
(33.7-43.2) compared with ACEi (60.1 %) 
and ARB (53.9 %). The number of serious 
adverse event incidents with aliskiren 
(3.4 %) was between ACEi (2.4 %) and ARB 
(8.4 %). Angioedema, urticaria and renal 
dysfunction were less than 0.5 % and hyper-
kalemia as low as 0.1 %. Hypotension 
(7.6 %) and peripheral edema (4.8 %) were 
the two most reported adverse events that 
occurred with aliskiren treatment. The inci-
dence of cough with aliskiren treatment was 
3.7 %, which was lower than that of ACEi 
treatment (12 %). Aliskiren at a dose of 
600 mg was related with diarrhea (White et 
al., 2010). 
Aliskiren combined with an ARB or 
HCTZ has a good safety profile, demonstrat-
ed by a meta-analysis of 10 randomized clin-
ical trials and a total of 4814 patients. How-
ever, serum potassium levels should be care-
fully monitored when using aliskiren with 
another RAAS blocking agent. There is a 
greater risk of hyperkalemia when aliskiren 
is used with ARB or ACEi than when ACEi 
or ARB (RR 1.58, 95 % CI 1.24–2.02) or 
aliskiren (1.67, 1.01–2.79) are used as a 
monotherapies, respectively.  There was no 
significant difference in acute kidney failure 
risk between the mono- and combined thera-
py (1.14, 0.68–1.89) (Harel et al., 2012). 
 
AVOID, ALTITUDE AND DUAL RAAS 
BLOCKADE 
In the AVOID (Aliskiren combined with 
losartan in type 2 diabetes and nephropathy) 
trial, 599 patients with hypertension and type 
2 DM and nephropathy who were taking 
100 mg losartan daily, received add-on 
aliskiren. This trial was randomized in 2 
arms; patients in one arm received 150 mg 
aliskiren for the first 3 months then the 
aliskiren dose was doubled, and the second 
arm was given placebo. Compared with pla-
cebo, aliskiren 300 mg showed a 20 % de-
cline in albumin/creatinine ratio (95 % con-
fidence interval, 9 to 30; p < .001). There 
was no difference in adverse events and seri-
ous adverse events between the groups. Con-
sidering the similar blood pressure reduc-
tions between the groups (systolic, 2 mm/Hg 
lower [P=.07] and diastolic, 1 mm/Hg lower 
[P=.08] in the aliskiren group), the renopro-
tective effect of aliskiren might be independ-
ent of blood pressure reduction (Parving et 
al., 2008).  
The ALTITUDE (Aliskiren Trial in Type 
2 Diabetes Using Cardio-renal Disease End-
points) study  investigated 300 mg add-on 
aliskiren to ACEi or ARB in patients with 
diabetes whose glomerular filtration rate 
(GFR) was lower than 60 ml/min per 
1.73 m2 or with microalbuminuria. The pri-
mary outcome in ALTITUDE was time to 
first event for the composite endpoint of car-
diovascular (CV) death, resuscitated death, 
myocardial infarction, stroke, unplanned 
hospitalization for heart failure (HF), onset 
of end-stage renal disease or doubling of 
baseline serum creatinine concentration 
(Parving et al., 2009). The study was termi-
nated early by the safety board due to in-
creased adverse events such as nonfatal 
stroke (2.6 % with aliskiren vs. 2 % placebo, 
unadjusted p = .04), renal impairment hyper-
kalemia and hypotension (McMurray et al., 
2012). This study concluded that aliskiren 
should not be combined with ACEi and ARB 
in patients with hypertension and diabetes or 
in the presence of moderate or worse renal 
impairment. 
In 2008, the ONTARGET (Ongoing 
Telmisartan Alone and in Combination With 
Ramipril Global Endpoint Trial) trial demon-
strated that a combination of ramipril and 
telmisartan decreased proteinuria better than 
both ramipril and telmisartan monotherapies. 
However, secondary renal outcomes, dialy-
sis, and serum creatinine doubling was high-
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er with ramipril and telmisartan combination 
therapy (Mann et al., 2008).  
ONTARGET raised questions about 
combining two RAAS blocking agents and 
the predictive value of surrogate biomarkers 
such as microalbuminuria. This trial, which 
recruited patients with hypertension and ath-
erosclerotic vascular disease or diabetes with 
end-organ damage who were prescribed co-
medication of ACEi and ARBs, resulted in 
an increase renal adverse event incidence 
such as dialysis use and increased serum cre-
atinine levels (Mann et al., 2008). On the 
other side, the ALTITUDE trial investigated 
cardio-renal hard endpoints of adding alis-
kiren to ACEi or ARB therapy in patients 
with diabetes and renal disease (GFR 
< 60 ml/min per 1.73 m2 or microalbuminu-
ria) (Parving et al., 2009). In this perspec-
tive, when ONTARGET and ALTITUDE 
were evaluated together in hypertensive pa-
tients with diabetes and renal disease; hyper-
kalemia, high serum creatinine, renal dys-
function and hypotension related with dual 
RAAS blockage increased. Interestingly, in 
ALTITUDE, adverse events like hyperkale-
mia and hypotension related with dual 
RAAS were predictable in trial hypertensive 
patients with diabetes and renal disease, but 
the increase in non-fatal stroke incidence 
was not and this finding sparked an argu-
ment concerning the use of dual RAAS 
blockade with aliskiren. This issue should be 
thoroughly investigated.  
New components of the RAAS pathway 
are frequently being discovered and evaluat-
ed in clinical trials. For example, in recent 
years prorenin, angiotensin IV, Angiotensin 
1-7 and ACE2 and more parameters of 
RAAS were investigated by researchers. 
However the roles or clinical impacts of 
these parameters are still not clear. In theory, 
inhibiting RAAS from two points could re-
sult in too much inhibition of positive com-
ponents of RAAS and thus the expected im-
provement might not be seen. 
The results of ATMOSPHERE (The 
Aliskiren Trial of Minimizing Outcomes for 
Patients with Heart Failure) trial has a very 
different design vs. ALTITUDE and by re-
cruiting a different patient’s population such 
as those with heart failure will give us addi-
tional information on dual RAAS blockade 
with aliskiren (McMurray at al., 2012) 
 
CONCLUSION 
The use of RAAS blockers in patients 
with diabetes and hypertension has positive 
effects and is recommended by guidelines. 
Aliskiren shows similar efficacy and safety 
when compared with the widely-used ACEi 
and ARBs. Though similar in efficacy and 
safety, in terms of pharmacoeconomics and 
place in therapy studies, as seen in every 
other new drug it has failed to show superi-
ority versus current treatments. The first re-
sults of the ASPIRE-HIGHER program con-
sisting of 14 major clinical trials and about 
35 000 patients reported very positive re-
sults. The perspective towards aliskiren 
changed after AVANT-GARDE (Aliskiren 
and Valsartan Versus Placebo in Lowering 
NT-proBNP in Patients Stabilized Following 
an Acute Coronary Syndrome) and ASPIRE 
(Effect of the direct renin inhibitor aliskiren 
on left ventricular remodelling following 
myocardial infarction with systolic dysfunc-
tion), and recently ALTITUDE, which was 
expected to have very positive results and 
more recently ASTRONAUT (Six Months 
Efficacy and Safety of Aliskiren Therapy on 
Top of Standard Therapy, on Morbidity and 
Mortality in Patients with Acute Decompen-
sated Heart Failure) because trials resulted 
with somehow disappointing results (Sen et 
al., 2013). However, it could be argued that 
the negative results were not solely related to 
aliskiren, but also to study designs, study 
population and dual RAAS blockade. In the 
next few years dual RAAS blockade, study 
populations, and surrogate markers like mi-
croalbuminuria will probably be discussed 
more. 
After ONTARGET, the ALTITUDE trial 
evaluated hard endpoints with a different 
study design. Dual RAAS blockade was ex-
pected to have a positive effect in patients 
with hypertension and diabetes. However, 
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the results brought about more questions. For 
the time being, according to current data, the 
combination of aliskiren with an ACEi or 
ARB is not recommended for hypertensive 
patients with diabetes or at least renal dys-
function, especially when we consider the 
risk of developing new adverse events such 
as hyperkalemia and hypotension. 
Dual RAAS blockade might have posi-
tive results in different patient groups such 
as those with heart failure or diabetes with 
other complications, excluding renal im-
pairment. Moreover, specific patients with 
high baseline PRA might be candidates for 
future clinical trials.  
According to regulations, in order to 
show efficacy of aliskiren in new indica-
tions, such as diabetes and heart failure, 
aliskiren should be added to the current op-
timal treatment. However, in these popula-
tions, the optimal treatment is mostly an 
ACEi or ARB.  Considering this, aliskiren 
should provide its benefits with dual RAAS 
blockage without any increase in the rate of 
adverse reactions. There are no more trials 
other than CHARM-added (Effects of Can-
desartan in Patients with CHF and Reduced 
Left-ventricular Systolic Function Taking 
Angiotensin-converting-enzyme Inhibitors), 
Val-HeFT (A randomized trial of the angio-
tensin-receptor blocker valsartan in chronic 
heart failure) and a few more highlighting 
benefits of dual RAAS blockage (McMurray 
et al., 2003; Nakao et al., 2003). Discordant 
results of different trials should be under-
stood well; trial designs and endpoints 
should be analyzed. Another fact is that we 
need more and better surrogate markers to 
better predict hard endpoints. Pharmacoeco-
nomic long-term benefits might also be in-
vestigated in clinical trials or real-life stud-
ies.  
Future clinical trials may focus on 
aliskiren combinations with HCTZ and/or 
CCB due to the disappointing results of dual 
RAAS blockade studies. Current data have 
substantiated the effectiveness of aliskiren as 
a monotherapy or in combination with 
HCTZ and/or calcium channel blockers. It is 
known that CCB treatment does not affect or 
improve metabolic parameters such as blood 
glucose and lipids. When this issue is taken 
into account, a combination of aliskiren and 
CCB may be a new option for patients with 
hypertension and diabetes.  
Although there was no evidence of harm 
with aliskiren treatment, the APOLLO trial, 
which was evaluating the effect of aliskiren 
alone and in combination with HCTZ or 
CCB on cardiovascular events in elderly 
people, was also terminated early. There is 
very limited information on the reason for 
termination of the APOLLO trial. On the 
other hand, initiation of aliskiren in addition 
to standard therapy demonstrated no benefi-
cial effect in mortality or hospitalization in 
heart failure patients in the ASTRONAUT 
trial. At this time, no trials using aliskiren 
with hard endpoints are expected in the near 
future (Mancia et al., 2013).  
Aliskiren is a relatively new drug that 
was approved by the FDA for the treatment 
of hypertension in 2007. Although in recent 
years it has proven its efficacy and placebo-
like safety profile in clinical trials, there are 
several issues to be clarified. In particular, 
there is a requirement for the thorough doc-
umentation of the clinical impact of lowering 
PRA activity, dual RAAS blockade, and the 
effect of (P)RR.  
As concluded by several studies, proren-
in may have a role beyond angiotensin for-
mation. Data on the function of (P)RR recep-
tor remains preclinical and unclear. To un-
derstand the RAAS system better and devel-
op new therapies in this area is exciting, but 
it remains unresolved for the time being. The 
effects of renin inhibitors on prorenin should 
be carefully investigated when we consider 
that high prorenin levels might be associated 
with diabetic complications in patients with 
hypertension. 
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